NEW YORK (GenomeWeb) – Interleukin Genetics today said that it will provide its genetic testing services to Isis Pharmaceuticals for a Phase II clinical study evaluating the novel therapeutic ISIS-APO(a)Rx in patients with high levels of lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.